Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067472 | 1.00 | ALDH1A1 (0.58) | ALDH1A1RAB9AMAPTNPC1ACP3 | |
| SCHEMBL23610038 | 1.00 | ALDH1A1 (0.58) | ALDH1A1RAB9AMAPTNPC1ACP3 | |
| SCHEMBL31143620 | 1.00 | ALDH1A1 (0.58) | ALDH1A1RAB9AMAPTNPC1ACP3 | |
| SCHEMBL31143595 | 1.00 | ALDH1A1 (0.58) | ALDH1A1RAB9AMAPTNPC1ACP3 | |
| SCHEMBL5205156 | 0.84 | ALDH1A1 (0.46) | ALDH1A1RAB9AMAPTNPC1HTT | |
| SCHEMBL9414517 | 0.80 | ACP3 (0.62) | ALDH1A1ACP3HTTL3MBTL1KMT2A | |
| SCHEMBL17064382 | 0.78 | ACP3 (0.49) | ALDH1A1RAB9AMAPTNPC1ACP3 | |
| SCHEMBL5654822 | 0.77 | PDE7A (0.54) | ALDH1A1RAB9AMAPTNPC1HTT | |
| SCHEMBL31067521 | 0.77 | SMN1; SMN2 (0.42) | ALDH1A1RAB9AMAPTNPC1HTT | |
| SCHEMBL5656690 | 0.77 | L3MBTL1 (0.44) | ALDH1A1RAB9AMAPTNPC1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-10-24 | — | — | US | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-13 | — | — | US | disclosed |
| US-10125102-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-13 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| EP-3113772-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134998-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ALDH1A1 1065/4885RAB9A 1612/4885MAPT 2830/4885 |
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885RAB9A 2189/4885MAPT 2984/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885RAB9A 2189/4885MAPT 2984/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885RAB9A 2189/4885MAPT 2984/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1220/4885RAB9A 1954/4885MAPT 3007/4885 |
| US-10329260-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ALDH1A1 1065/4885RAB9A 1612/4885MAPT 2830/4885 |
| US-10125102-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ALDH1A1 1065/4885RAB9A 1612/4885MAPT 2830/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ALDH1A1 1065/4885RAB9A 1612/4885MAPT 2830/4885 |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ALDH1A1 1065/4885RAB9A 1612/4885MAPT 2830/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885RAB9A 2189/4885MAPT 2984/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885RAB9A 2189/4885MAPT 2984/4885 |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ALDH1A1 1065/4885RAB9A 1612/4885MAPT 2830/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885RAB9A 2189/4885MAPT 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.